All In Biotech

Drug Trial Radar · NCT07735637

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Nov 2, 2028

Study completion Nov 17, 2039

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete response (CR) rate at 9 months as assessed by Blinded Independent Central Review (BICR), in participants with TE NDMM. Study details include: * The study duration is estimated to be up to 13 years from the date the first participant is randomised. * For participants in Arm A (AZD0120), the total duration of participant follow-up will be 15 years (including a Long Term Follow-up study) after the last participant has received the AZD0120 infusion. * The treatment duration will be:- Arm A (AZD0120): lymphodepletion over 3 days, a single-day infusion of AZD0120, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment. * Arm B (ASCT): conditioning therapy over 24 to 48 hours, ASCT, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment. Disclosure Statement: This is an open-label, randomised study with 2 treatment arms.

Conditions

  • Newly Diagnosed Multiple Myeloma (NDMM)

Interventions

  • AZD0120Biological

    Arm A: AZD0120 - autologous BCMA/CD19 dual-targeting CAR-T cells. Participants will receive lymphodepletion conditioning (cyclophosphamide and fludarabine) followed by AZD0120 CAR-T cell infusion.

  • CyclophosphamideDrug

    Arm A: Cyclophosphamide will be given intravenously as lymphodepletion conditioning.

  • FludarabineDrug

    Arm A: Fludarabine will be given intravenously as lymphodepletion conditioning.

  • Melphalan (part of ASCT)Drug

    Arm B - Autologous stem cell transplant: High-dose melphalan will be given over 1-2 days, followed by autologous stem cell rescue.

  • LenalidomideDrug

    Arm A and Arm B: Lenalidomide maintenance treatment will be started in both Arm A and Arm B after AZD0120 therapy or ASCT, respectively. Lenalidomide maintenance on study will be continued up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 13 years.
  2. Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)Time frame: Up to approximately 13 years.

Locations

114 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona · Not yet recruiting

  • Research Site

    Goodyear, Arizona · Not yet recruiting

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Los Angeles, California · Withdrawn

  • Research Site

    Orange, California · Not yet recruiting

  • Research Site

    San Francisco, California · Not yet recruiting

  • Research Site

    Stanford, California · Not yet recruiting

  • Research Site

    Denver, Colorado · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Newnan, Georgia · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Zion, Illinois · Not yet recruiting

  • Research Site

    Lexington, Kentucky · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Detroit, Michigan · Not yet recruiting

  • Research Site

    Rochester, Minnesota · Not yet recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    Great Neck, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Rochester, New York · Not yet recruiting

  • Research Site

    Stony Brook, New York · Not yet recruiting

  • Research Site

    The Bronx, New York · Not yet recruiting

  • Research Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Research Site

    Charlotte, North Carolina · Not yet recruiting

  • Research Site

    Durham, North Carolina · Not yet recruiting

  • Research Site

    Winston-Salem, North Carolina · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Columbus, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Philadelphia, Pennsylvania · Not yet recruiting

  • Research Site

    Philadelphia, Pennsylvania · Not yet recruiting

  • Research Site

    Austin, Texas · Not yet recruiting

  • Research Site

    Dallas, Texas · Not yet recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.